
Once hailed as a landmark breakthrough in diabetes care, semaglutide is now facing a wave of complex litigation that is fundamentally reshaping its market presence. As reports of serious adverse events associated with semaglutide (the active compound in Ozempic®, and Wegovy®, Rybelsus®, Mounjaro®, or Zepbound®) have mounted, so too have the lawsuits targeting manufacturers and …







